Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/E ratio high or low?
The P/E ratio of 40.28 is 25% below its 1-year average of 54.06, near the low end of its 1-year range (40.28–66.76).
As of 2026-10-06T16:40:48.425Z.
Calculation as of: 2026-10-06T16:40:48.425Z.
Quote observation: 2026-10-06T16:40:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47b7d046e53ba400f53df530976eb059ace8f079140d97e9bcfa36b682aba175
PE Ratio (40.28) = Close Price ($22.16) / Diluted TTM EPS ($0.55)
PE RATIO
40.28
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
25.49
median of 175 covered companies
CURRENT VS SECTOR MEDIAN
+58.02%
vs the sector median at left
Market Cap
$438.81M
PE Ratio
N/A
TTM Avg
139.84
3Y Avg
139.84
5Y Avg
139.84
Market Cap
$423.35M
PE Ratio
N/A
TTM Avg
193.87
3Y Avg
193.87
5Y Avg
193.87
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Assembly Biosciences, Inc. (ASMB) | $439.05M | 40.28 | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $438.81M | N/A | 139.84 | 139.84 | 139.84 |
| NeuroPace, Inc. (NPCE)vs › | $445.61M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $434.30M | N/A | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $447.04M | N/A | 2.09 | 2.09 | 2.09 |
| NeoGenomics, Inc. (NEO)vs › | $431.02M | N/A | 138.05 | 184.03 | 168.06 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $447.77M | N/A | N/A | N/A | N/A |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $423.35M | N/A | 193.87 | 193.87 | 193.87 |
| Senseonics Holdings, Inc. (SENS)vs › | $422.12M | N/A | 7.35 | 7.35 | 7.35 |
| Rezolute, Inc. (RZLT)vs › | $420.32M | N/A | N/A | N/A | N/A |
At 40.3, P/E is below its 1-year median — higher than 0% of readings in its 1-year history.
1-year low
41.0
median
55.0
1-year high
66.8
Trailing P/E
40.3
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$22.16
Forward EPS (Est.)
$-0.61
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2026-10-05 | 41.35 |
| 2026-10-02 | 40.98 |
| 2026-10-01 | 41.78 |
| 2026-09-30 | 42.71 |
| 2026-09-29 | 42.69 |
| 2026-09-28 | 42.93 |
| 2026-09-25 | 43.04 |
| 2026-09-24 | 43.02 |
| 2026-09-23 | 43.58 |
| 2026-09-22 | 46.27 |
| 2026-09-21 | 46.25 |
| 2026-09-18 | 45.40 |
| 2026-09-17 | 46.07 |
| 2026-09-16 | 46.33 |
| 2026-09-15 | 47.47 |
| 2026-09-14 | 52.65 |
| 2026-09-11 | 54.18 |
| 2026-09-10 | 55.38 |
| 2026-09-09 | 59.76 |
| 2026-09-08 | 64.15 |
| 2026-09-04 | 66.55 |
| 2026-09-03 | 65.69 |
| 2026-09-02 | 66.76 |
| 2026-09-01 | 63.96 |
| 2026-08-31 | 61.15 |
| 2026-08-28 | 61.95 |
| 2026-08-27 | 63.27 |
| 2026-08-26 | 64.40 |
| 2026-08-25 | 64.24 |
| 2026-08-24 | 64.15 |
| 2026-08-21 | 62.51 |
| 2026-08-20 | 60.96 |
| 2026-08-19 | 61.53 |
| 2026-08-18 | 58.42 |
| 2026-08-17 | 54.56 |
| 2026-08-14 | 59.91 |